Advertisement
Advertisement
Trending on CancerNetwork
1
Prescribing Exercise in Oncology: Moving Beyond “Good Luck”
2
85 rwpCR and rwEFS in Early-Stage Triple-Negative Breast Cancer Patients From Community Oncology Are Concordant With Trial End Point Estimates
3
86 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results From VIKTORIA-1
4
FDA Accepts NDA, Grants Priority Review to Bezuclastinib/Sunitinib in Pretreated GIST
5